When: RSI bullish divergence at oversold levels

Then: Re-engagement trigger 3 of 4

When: Forward EPS reaffirmation at $6.00+ with Nutrition stabilization

Then: Re-engagement trigger 4 of 4

TRIM TO UNDERWEIGHT: Sell into weakness to reduce exposure by one-third to one-half, cap equity exposure at 3-4%, hold the dividend-paying core, set stop at $105.

• Technical structure is genuinely bearish with Q1 $20B debt issuance, negative tangible book value, and $35B goodwill integration overhang
• 2.49% yield on $7.2B free cash flow with 1.7x dividend coverage provides real income while waiting
• Dividend recovery math (13 years to recover $34 loss) is flawed as it ignores price recovery and total return context
• Low beta of 0.59 provides defensive characteristics; January-May 2026 35% drawdown was idiosyncratic to acquisition announcement
• MACD negative, RSI at 35, price below 50 and 200 day MAs - already priced into trader recommendation
• Trim already reduces exposure to EPS recovery risk (projected $3.09 to $6.07, 96% recovery)
• Full sell removes lowest correlation asset during 97% odds of zero Fed cuts and 8% recession probability
• Stops do not execute cleanly in low-liquidity defensive names; ABT demonstrated 35% moves on company-specific news
• Aggressive analyst's 2:1 risk/reward with $105 stop and $92-95 targets is theoretical; stops can gap
• $174B market cap defensive healthcare blue chip in S&P 100; lack of retail engagement is expected, not bearish
• Full exit locks in losses on a name that pays yield to wait through uncertainty

→ vs aggressive: The aggressive analyst wants full exit to sell, but conservative argues underweight is sufficient - the same conclusion without unnecessary costs

→ vs aggressive: Dividend recovery math of 13 years ignores total return framework and real quarterly income generation from 2.49% yield

→ vs aggressive: Bearish technicals are already priced into the trader recommendation to trim to underweight; arguing for the same action with extra steps is counterproductive

→ vs aggressive: Risk/reward framing assumes clean stop execution at $105 and orderly target achievement at $92-95, but stops gap in low-liquidity defensive names

→ vs aggressive: Forward earnings recovery concerns justify trim, not full exit - conservative position already reduces exposure to that specific risk by one-third to one-half

→ vs aggressive: Reddit silence argument is weakest part of case - ABT is $174B market cap defensive blue chip; lack of retail chatter is expected state, not a fragile bid signal

→ vs aggressive: Removing lowest beta holding during higher for longer rate regime with 8% recession probability strips necessary defensive ballast from portfolio

SELL (partial trim to underweight); refine execution with wider stop, sequenced trim, and explicit re-entry criteria

• MACD at negative 1.75 with histogram widening to negative 0.38; RSI at 35.33 with no bullish divergence; both SMAs sloping down with price below them
• Trim to underweight at 50-75% of benchmark weight, absolute exposure capped at 3-4% of portfolio equity
• Stop should be widened to 106.50-107 (ATR of 2.28 makes 105 too tight at only ~1.7% above price)
• Sequence trim into thirds: one-third now, one-third on move toward 105, final third on break below 98 or failed relief rally
• Re-entry trigger: confirmed close above 200 SMA at 103.63 on rising volume, followed by reclaim of 50 SMA at 107 with RSI bullish divergence
• Operating margin compressed to 12.1% in Q1 2026; company carrying $34 billion in total debt with negative tangible book and goodwill overhang
• Low 0.59 beta did not protect against 35% drawdown between January-May 2026; idiosyncratic risk crystallized despite market correlation
• Dividend yield 2.49% with 1.7x FCF coverage currently adequate but at risk if Q2/Q3 show further margin compression or synergy delays
• 98 level is structural risk control; 105 stop is mechanical risk control—these must be differentiated
• Macro reinforces trim: 97% no-cut pricing, 8% recession probability, higher-for-longer punishing leveraged names
• Lingo and Volt PFA are 2027 catalysts, not 2026; $385 million formula settlement is sized but defined—neither moves 6-12 month thesis

→ vs aggressive: Full exit overreaches—trim already delivers most convexity benefit while preserving capital for re-entry; 13-year dividend recovery math is technically correct but analytically incomplete as dividend provides carry while waiting for price recovery or fundamental confirmation

→ vs conservative: Beta argument ignores the 35% idiosyncratic drawdown between January-May 2026; dividend defense needs sharper edge given margin compression, leverage build, and integration costs running hot; technical deterioration dismissal too casual, treating trim as static rather than ongoing process requiring re-evaluation if price breaks below 98